Inhibition of AGEs-RAGE-PP2A Axis Alleviates Cognitive Impairment after Chronic Heart Failure.


Journal

Cellular and molecular biology (Noisy-le-Grand, France)
ISSN: 1165-158X
Titre abrégé: Cell Mol Biol (Noisy-le-grand)
Pays: France
ID NLM: 9216789

Informations de publication

Date de publication:
31 May 2023
Historique:
received: 07 04 2023
medline: 12 8 2023
pubmed: 12 8 2023
entrez: 12 8 2023
Statut: epublish

Résumé

To investigate the effect of the AGEs-RAGE-PP2A axis on cognitive impairment (CI) after chronic heart failure (CHF). Mice were divided into six groups: Sham, TAC, Sham+RAGE-/-, TAC+RAGE-/-, AG, and FTY720 group. AG mice and FTY720 mice were treated with AGEs inhibitor (aminoguanidine, AG) and PP2A activator (FTY720) respectively after TAC surgery. The cardiac function of AG and TAC+RAGE-/- mice was significantly better than that of TAC mice (P<0.05). However, the heart function of FTY720 mice were just improved a part of that. To behavioral function, the escape latency period of the TAC+RAGE-/-, AG and FTY720 mice were significantly shorter (P<0.05), and the times of platform crossings and residence time of them were significantly improved (P<0.05). HE staining and silver staining show the structure of TAC+RAGE-/-, AG and FTY720 mice were more complete. Also, in these three groups, the expression of Aβ and p-tau protein in the brain can be significantly down-regulated (P<0.05) and the PP2A protein expression level was up-regulated (P<0.05). And the expression of hippocampal Bax, Cyt-C, and Caspase-3 of that were all down-regulated (P<0.05), and Bcl-2 was up-regulated (P<0.05). Deficient of AGEs, RAGE and activating PP2A can significantly attenuate the cognitive impairment in CHF mice, and protect the brain structure. This mechanism seems via reducing the expression of Aβ, p-tau, and apoptotic protein.

Identifiants

pubmed: 37571882
doi: 10.14715/cmb/2023.69.5.28
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

179-185

Auteurs

Shaodong Li (S)

The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. jishaokang19750515@163.com.

Linhai Wang (L)

The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. mimoulin19640611@163.com.

Junyan Wang (J)

The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. bxnnx1@163.com.

Birong Liang (B)

The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. huiliangcu19790617@163.com.

Wenbin Gao (W)

The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. zhanggawen19830912@163.com.

Yusheng Huang (Y)

The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. huangpan19950419@163.com.

Bo Deng (B)

The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. lidenghe19820813@163.com.

Qing Liu (Q)

The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. aoshiqing62399@126.com.

Zheng Zhou (Z)

Chinese Medicine Department, Zhaoqing Medical College, Zhaoqing, 526000, China. auoaw1@163.com.

Lu Zhang (L)

The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. zhang325593yang725@163.com.

Shaoxiang Xian (S)

The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. egqsw9@163.com.

Lingjun Wang (L)

The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. smu868@126.com.

Jing Liu (J)

The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. weather8lj@126.com.

Zhaohui Wang (Z)

The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. 971434900@qq.com.

Classifications MeSH